On Oct 31, major Wall Street analysts update their ratings for $Exelixis (EXEL.US)$, with price targets ranging from $29 to $38.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $30.
BofA Securities analyst Jason Gerberry maintains with a buy rating.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $31 to $38.
Wells Fargo analyst Derek Archila maintains with a buy rating, and adjusts the target price from $32 to $36.
TD Cowen analyst Yaron Werber maintains with a buy rating, and maintains the target price at $34.
Furthermore, according to the comprehensive report, the opinions of $Exelixis (EXEL.US)$'s main analysts recently are as follows:
Exelixis' third quarter showed robust performance for Cabometyx, with net product sales exceeding expectations by approximately 8% and achieving 12% growth compared to the previous year. The consistent revenue generation from Cabometyx and the promising prospects of the pipeline, particularly through zanzalintinib, are seen as significant potential contributors to future performance.
Exelixis' third-quarter cabo revenues surpassed expectations, coming in at $478.1 million, which reflects a 4.7% beat over the consensus. This performance is attributed to an uptick in cabo market share and an increase in new patient starts. Concurrently, the management has revised its future net product revenue and total revenue guidance upwards by 5.6% and 7.4% respectively. Despite this positive outlook, a cautious stance is maintained regarding zanza until further late-stage data is available to justify increased estimates.
Here are the latest investment ratings and price targets for $Exelixis (EXEL.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$伊克力西斯 (EXEL.US)$的评级，目标价介于29美元至38美元。
摩根士丹利分析师Jeffrey Hung维持持有评级，维持目标价30美元。
美银证券分析师Jason Gerberry维持买入评级。
花旗分析师David Lebowitz维持买入评级，并将目标价从31美元上调至38美元。
富国集团分析师Derek Archila维持买入评级，并将目标价从32美元上调至36美元。
TD Cowen分析师Yaron Werber维持买入评级，维持目标价34美元。
此外，综合报道，$伊克力西斯 (EXEL.US)$近期主要分析师观点如下：
伊克力西斯的第三季度在Cabometyx方面表现强劲，净产品销售超出预期约8%，与去年同期相比实现12%的增长。Cabometyx持续稳定的营业收入以及通过zanzalintinib尤其是管线的前景被视为未来业绩的重要潜在贡献者。
伊克力西斯的第三季度cabo营收超出预期，达到了47810万美元，比市场共识高出4.7%。这一业绩归因于cabo市场份额的提升和新患者的增加。同时，管理层将未来净产品收入和总收入指引上调了分别5.6%和7.4%。尽管存在这种积极前景，但在获得进一步late-stage数据支持增加预估之前，对zanza仍持谨慎态度。
以下为今日10位分析师对$伊克力西斯 (EXEL.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
